Epitopes involved in antibody-mediated protection from Ebola virus.
about
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1A structurally distinct human mycoplasma protein that generically blocks antigen-antibody unionFDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesEbola haemorrhagic feverMonitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in LiberiaPlant-produced candidate countermeasures against emerging and reemerging infections and bioterror agentsEbolavirus comparative genomicsMouse models for filovirus infectionsStructural basis for differential neutralization of ebolavirusesAntigenic subversion: a novel mechanism of host immune evasion by Ebola virusNeutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against itEbolavirus glycoprotein structure and mechanism of entryComplex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light ChainTechniques and tactics used in determining the structure of the trimericebolavirusglycoproteinA shared structural solution for neutralizing ebolavirusesStructure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola VirusStructural and molecular basis for Ebola virus neutralization by protective human antibodiesCell-targeting antibodies in immunity to EbolaBoth Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like DomainProduction of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal CattleRapid high yield production of different glycoforms of Ebola virus monoclonal antibodyEnhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola VirusEbola virus: A gap in drug design and discovery - experimental and computational perspective.Monoclonal antibodies for the treatment of Ebola virus disease.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular EntryA screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.Discovery of an antibody for pan-ebolavirus therapySpatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography.Impact of spatial dispersion, evolution, and selection on Ebola Zaire Virus epidemic wavesAnalysis of Venezuelan equine encephalitis replicon particles packaged in different coats.Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.Comprehensive analysis of ebola virus GP1 in viral entry.Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virusDiscovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entryVaccinating captive chimpanzees to save wild chimpanzees.Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.Infectivity-enhancing antibodies to Ebola virus glycoprotein.
P2860
Q24329246-C96A8D98-5EB5-4684-9529-FD1FBB2B742FQ24568048-C55EBBAE-EE02-44AB-91FC-C2427BD79E76Q24568225-985F3EE9-4070-4603-ABC9-3D7DDC966828Q24612811-D58C7C07-A1FC-460F-9E33-996984906C19Q24629338-50281827-1779-4150-BADE-E6F29CEC68ACQ24696012-F3FDD6C0-D5E0-4585-9482-595914331B88Q26783107-89C64991-34F3-4E71-9C9A-1220625B0E56Q26801790-039738F7-DEBD-482F-ACF1-CC6B990ED13CQ27011569-5E637DDD-F24E-4A69-A7DF-0F3937510407Q27014910-999CB5A9-98C0-448F-9C0D-05269BED775FQ27339643-06C5F3C6-E102-4941-A499-06EF7C7E1CE5Q27489891-F37D6C87-6467-4BAB-90C5-E0C54ECFAE69Q27490991-890F2347-762A-46B8-B524-6EB33BB0320AQ27649064-AF47311F-E563-434E-A455-32D8A4120E2EQ27658238-4D400312-C7C2-4255-A5B6-F659879CC3C8Q27675675-5BB41453-45B2-4020-AB4A-3B1DD267F296Q27676230-1BDEC064-60C3-4824-BD51-650156BE23CAQ27704188-45899BC2-348D-4886-BDF6-A3576E92CB87Q28068972-2FAC7285-5157-4E4B-B2F7-4FD3FC146A43Q28596689-EC4E6369-5FA0-4807-8B52-183068C0281CQ28603849-90527074-9628-48F2-AF37-17759771C848Q28743509-22383875-F923-4986-80D6-DEDA691AFBD3Q30224854-1721E907-971E-408C-8ACE-635EF56010D1Q30235073-710F0BB3-EDC2-4E89-920E-76A85FC5202EQ30243938-90B9B206-B43A-415E-8FA1-41D29C8A8E47Q30245073-1E1E5C6A-0CCD-4904-B10A-34A8E5BB4B67Q30252022-9B7C8EC3-C4BC-46F1-9D1B-3B060B4BD252Q30276615-EFCEEDF2-922A-44D2-B0D3-37D22935EB0CQ30279239-61B0B974-3F1F-4EA3-B800-04FA51B4D480Q30385927-344749B6-9F4C-47F0-B416-B6C62DBD3918Q30409973-CCA4AFF6-8E4E-4E24-A3B8-1EA50C7EB4E6Q30650455-0DE624E0-38E7-4187-84C6-DEDD82B26937Q33351971-725278BB-6D8A-4DAF-8EB9-E88414E8445FQ33619065-88B118ED-7B96-4869-AB86-60123127E936Q33724185-1AC6C7B0-0ED7-4616-9C37-A521482B6E90Q33733844-7A3ADEC8-5E43-4CCB-8537-9B294CE08DD9Q33785133-959B0B2A-6085-4307-8507-A3CE241C6F47Q33790197-E0CA3381-3724-4203-9D32-54D1F5D14430Q33840716-28E981F9-9F18-4D3A-8329-CA3C1E341CC6Q33850720-9DECB384-1482-4137-8A0A-D8D3D426A0D8
P2860
Epitopes involved in antibody-mediated protection from Ebola virus.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Epitopes involved in antibody-mediated protection from Ebola virus.
@en
type
label
Epitopes involved in antibody-mediated protection from Ebola virus.
@en
prefLabel
Epitopes involved in antibody-mediated protection from Ebola virus.
@en
P2093
P1433
P1476
Epitopes involved in antibody-mediated protection from Ebola virus.
@en
P2093
Schmaljohn AL
P304
P356
10.1126/SCIENCE.287.5458.1664
P407
P577
2000-03-01T00:00:00Z